Form D · Pharmaceuticals

ADYNXX, INC.

San Francisco, CA · CIK 0001427066

Offering snapshot reported Jan 19, 2017 · SEC filing

Reported sold
$16M
Offering amount: $16M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 20, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 19, 2017Initial$15,999,999No comparison3SEC filing
Dec 27, 2010Initial$4,803,858No comparison8SEC filing
Dec 8, 2010Initial$39,098No comparison10SEC filing
Aug 3, 2010Initial$740,560No comparison8SEC filing
Feb 12, 2008PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-278775
$2,026,849 of the Total Amount Sold was in the form of converted Promissory Notes.

Source: Form D, filed Jan 19, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Stan Abel Director
Michael Ashley Director
George Barnett Director
Scott Harris Executive
Heath Lukatch Director
Julien Mamet Director, Executive
Donald Manning Executive
Rick Orr Director, Executive
Dennis Podlesak Director
Eckard Weber Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
100 Pine Street Suite 500
San Francisco, CA, 94111